Related Experiment Video
Updated: Jun 25, 2026
Monitoring Dendritic Cell Migration using 19F / 1H Magnetic Resonance Imaging
Published on: March 20, 2013
Semiquantitation of mouse dendritic cell migration in vivo using cellular MRI
Gregory A Dekaban1, Jonatan Snir, Bradly Shrum
1Biotherapeutics Research Group, University of Western Ontario, London, Ontario, Canada.
Abstract:
Despite recent therapeutic advances, including the introduction of novel cytostatic drugs and therapeutic antibodies, many cancer patients will experience recurrent or metastatic disease. Current treatment options, particularly for those patients with metastatic breast, prostate, or skin cancers, are complex and have limited curative potential. Recent clinical trials, however, have shown that cell-based therapeutic vaccines may be used to generate broad-based, antitumor immune responses. Dendritic cells (DC) have proved to be the most efficacious cellular component for therapeutic vaccines, serving as both the adjuvant and antigen delivery vehicle. At present it is not possible to noninvasively determine the fate of DC-based vaccines after their administration to human subjects. In this study, we demonstrate that in vitro-generated mouse DC can be readily labeled with superparamagnetic iron oxide nanoparticles, Feridex, without altering cell morphology, or their phenotypic and functional maturation. Feridex-labeling enables the detection of DC in vivo after their migration to draining lymph nodes using a 1.5 T clinical magnetic resonance scanner. In addition, we report a semiquantitative approach for analysis of magnetic resonance images and show that the Feridex-induced signal void volume, and fractional signal loss, correlates with the delivery and migration of small numbers of in vitro-generated DC. These findings, together with ongoing preclinical studies, are key to gaining information critical for improving the efficacy of therapeutic vaccines for the treatment cancer, and potentially, chronic infectious diseases.
Insights
Researchers labeled dendritic cells (DCs) with iron nanoparticles for tracking. This magnetic resonance imaging technique allows noninvasive monitoring of DC vaccine migration in vivo, crucial for improving cancer immunotherapy efficacy.
Area of Science:
- Immunology
- Biomedical Imaging
- Nanotechnology
Background:
- Cancer therapies face challenges with recurrent or metastatic disease, especially in breast, prostate, and skin cancers.
- Cell-based therapeutic vaccines show promise for generating antitumor immune responses.
- Dendritic cells (DCs) are effective cellular components for therapeutic vaccines, acting as adjuvant and antigen delivery vehicles.
Purpose of the Study:
- To develop a noninvasive method for tracking the in vivo fate of dendritic cell (DC)-based vaccines.
- To assess the feasibility of labeling DCs with superparamagnetic iron oxide nanoparticles (Feridex) for magnetic resonance imaging (MRI).
Main Methods:
- In vitro-generated mouse DCs were labeled with Feridex nanoparticles.
- Cell morphology, phenotype, and function were assessed post-labeling.
- DC migration to draining lymph nodes was detected in vivo using a 1.5 T clinical MRI scanner.
- A semiquantitative analysis of MRI data was developed to correlate signal changes with DC migration.
Main Results:
- Feridex labeling did not alter DC morphology, phenotype, or functional maturation.
- Labeled DCs were successfully detected in vivo within draining lymph nodes using MRI.
- MRI signal void volume and fractional signal loss correlated with the delivery and migration of DCs.
Conclusions:
- Feridex labeling provides a noninvasive method to track DC vaccine migration in vivo using MRI.
- This technique is critical for optimizing the efficacy of DC-based therapeutic vaccines for cancer treatment.
- Findings support further preclinical studies to enhance therapeutic vaccine effectiveness.
